	US 12,268,728 B2
	Composition for preventing or treating pulmonary diseases comprising hyaluronan and proteoglycan link protein 1
Dae Kyong Kim, Gyeonggi-do (KR); Yong Wei Piao, Seoul (KR); Ji Min Jang, Seoul (KR); Dan Zhou, Seoul (KR); So Yoon Yun, Seoul (KR); and Bo Kyung Park, Seoul (KR)
Assigned to HAPLNSCIENCE, INC., Gyeonggi-do (KR)
Appl. No. 17/287,443
Filed by HAPLNSCIENCE INC., Gyeonggi-do (KR)
PCT Filed Feb. 2, 2021, PCT No. PCT/KR2021/001374 § 371(c)(1), (2) Date Apr. 21, 2021, PCT Pub. No. WO2021/158000, PCT Pub. Date Aug. 12, 2021.
Claims priority of application No. 10-2020-0012742 (KR), filed on Feb. 3, 2020.
Prior Publication US 2022/0305077 A1, Sep. 29, 2022
Int. Cl. A61K 38/00 (2006.01); A23L 33/17 (2016.01); A61K 38/17 (2006.01); A61P 11/00 (2006.01); C07K 14/78 (2006.01)

CPC A61K 38/1709 (2013.01) [A23L 33/17 (2016.08); A61P 11/00 (2018.01); C07K 14/78 (2013.01); C07K 2319/02 (2013.01); C07K 2319/21 (2013.01); C07K 2319/50 (2013.01)]

8 Claims

1. A method of treating pulmonary disease, comprising administering to a subject in need thereof a pharmaceutical composition comprising hyaluronan and proteoglycan link protein 1 (HAPLN1) protein, wherein the pulmonary disease is chronic bronchitis, asthma, emphysema, or chronic obstructive pulmonary disease (COPD), the HAPLN1 protein comprises SEQ ID NO: 1, and the pharmaceutical composition improves alveolar damage caused by aging or elastic reduction.